Blueprint Medicines (BPMC) was downgraded to a Hold Rating at TD Cowen
TD Cowen analyst Marc Frahm downgraded Blueprint Medicines (BPMC – Research Report) to a Hold today and set a price target of $130.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Inozyme Pharma, and Xilio Therapeutics. According to TipRanks, Frahm has an average return of 3.7% and a 39.53% success rate on recommended stocks.
In addition to TD Cowen, Blueprint Medicines also received a Hold from J.P. Morgan’s Brian Cheng in a report issued today. However, on the same day, Citi reiterated a Sell rating on Blueprint Medicines (NASDAQ: BPMC).
The company has a one-year high of $121.90 and a one-year low of $73.04. Currently, Blueprint Medicines has an average volume of 988.3K.
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in March 2025, Jeffrey Albers, a Director at BPMC sold 5,766.00 shares for a total of $512,020.80.
Read More on BPMC:
Disclaimer & DisclosureReport an Issue
- Blueprint downgraded to Peer Perform from Outperform at Wolfe Research
- Blueprint Medicines downgraded to Neutral from Overweight at JPMorgan
- Blueprint Medicines downgraded to Perform from Outperform at Oppenheimer
- Blueprint Medicines downgraded to Sector Perform from Outperform at Scotiabank
- Blueprint Medicines downgraded to Hold from Buy at Needham
